Brain Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Brain Cancer Market Outlook
Thelansis’s “Brain Cancer Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Brain Cancer treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Brain Cancer Overview
Brain
cancer refer to abnormal growth of brain or central nervous system (CNS) cells.
These abnormal cells form a mass called a tumor, which can interfere with
normal brain functions. It can be primary or secondary. Primary brain tumors
originate in the brain and can be benign or malignant. Benign tumors are
noncancerous and grow slowly. They do not invade nearby tissues and are less
likely to recur after treatment. Malignant tumors, on the other hand, are
cancerous and grow rapidly. They invade surrounding tissues and may recur even
after treatment. Secondary brain tumors originate in different body parts and
spread to the brain. Cancer cells from primary tumors in organs such as the
lung, breast, kidney, colon, or stomach can travel through the bloodstream or
lymphatic system and form secondary tumors in the brain. Approximately 20% of
brain cancer cases are due to brain metastasis. Brain cancer symptoms can vary
depending on the location and size of the tumor. Common symptoms include
frequent headaches, seizures, changes in vision (such as double vision or
blurred vision), hearing and speech problems, difficulty with balance and
coordination, cognitive changes, and personality changes. However, these
symptoms can also be caused by other conditions, so it’s important to consult a
healthcare professional for an accurate diagnosis. Brain tumors are classified
into grades based on their growth rate and aggressiveness. The grading system
helps determine the treatment approach and prognosis. High-grade tumors, also
known as malignant or aggressive tumors, grow rapidly and are more likely to
spread to other brain or spinal cord parts. Low-grade tumors, also called
benign or slow-growing tumors, tend to grow more slowly and are less likely to
invade surrounding tissues. Diagnosis of brain cancer typically involves a
combination of imaging tests, such as magnetic resonance imaging (MRI) or
computed tomography (CT) scans, and a biopsy, which involves the removal of a
small sample of the tumor for examination under a microscope. Brain cancer
treatment options include surgery, radiation therapy, and chemotherapy. The
choice of treatment depends on various factors, including the type and grade of
the tumor, its size and location, the patient’s age and overall health, and the
presence of any genetic mutations or biomarkers. In 2023, an estimated 24,810
adults will be diagnosed with primary cancerous brain and spinal cord tumors in
the United States. Of these, 14,280 will be men and 10,530 will be women. Brain
tumors account for 85% to 90% of all primary central nervous system (CNS)
tumors.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment